BRPI0817879A2 - Composições e métodos de uso de anticorpos contra esclerostina - Google Patents

Composições e métodos de uso de anticorpos contra esclerostina

Info

Publication number
BRPI0817879A2
BRPI0817879A2 BRPI0817879-8A2A BRPI0817879A BRPI0817879A2 BR PI0817879 A2 BRPI0817879 A2 BR PI0817879A2 BR PI0817879 A BRPI0817879 A BR PI0817879A BR PI0817879 A2 BRPI0817879 A2 BR PI0817879A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
sclerostine
antibodies
sclerostine antibodies
Prior art date
Application number
BRPI0817879-8A2A
Other languages
English (en)
Inventor
Michaela Kneissel
Christine Halleux
Beate Diefenbach-Streiber
Josef Prassler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40219404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817879(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0817879A2 publication Critical patent/BRPI0817879A2/pt
Publication of BRPI0817879B1 publication Critical patent/BRPI0817879B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
BRPI0817879-8A 2007-10-12 2008-10-10 Anticorpos isolados contra esclerostina, usos dos mesmos, e composição farmacêutica BRPI0817879B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07118414 2007-10-12
EP07118414.7 2007-10-12
EP08151911.8 2008-02-25
EP08151911 2008-02-25
EP08161342 2008-07-29
EP08161342.4 2008-07-29
PCT/EP2008/063691 WO2009047356A1 (en) 2007-10-12 2008-10-10 Compositions and methods for use for antibodies against sclerostin

Publications (2)

Publication Number Publication Date
BRPI0817879A2 true BRPI0817879A2 (pt) 2014-06-17
BRPI0817879B1 BRPI0817879B1 (pt) 2025-02-11

Family

ID=

Also Published As

Publication number Publication date
MA31760B1 (fr) 2010-10-01
EA201000559A1 (ru) 2010-10-29
JP5913181B2 (ja) 2016-04-27
HRP20140161T1 (hr) 2014-03-28
PL2586796T3 (pl) 2017-05-31
US20120276591A1 (en) 2012-11-01
NZ584158A (en) 2011-10-28
US20110052592A1 (en) 2011-03-03
CN101821291A (zh) 2010-09-01
HK1143173A1 (en) 2010-12-24
AU2008309514A1 (en) 2009-04-16
CY1118691T1 (el) 2017-07-12
LT2586796T (lt) 2017-02-27
HRP20170347T1 (hr) 2017-08-11
CO6270368A2 (es) 2011-04-20
SI2203478T1 (sl) 2014-03-31
HUE031995T2 (en) 2017-08-28
KR101268675B1 (ko) 2013-06-25
TW200922621A (en) 2009-06-01
JP2013153757A (ja) 2013-08-15
JP6401196B2 (ja) 2018-10-03
CA2702005C (en) 2016-06-14
HN2010000674A (es) 2013-02-04
PE20091221A1 (es) 2009-09-11
ZA201001789B (en) 2011-12-28
DK2586796T3 (en) 2017-02-13
PL2203478T3 (pl) 2014-05-30
CA2702005A1 (en) 2009-04-16
TWI489993B (zh) 2015-07-01
MY152282A (en) 2014-09-15
IL204510A (en) 2013-01-31
EP2203478A1 (en) 2010-07-07
SI2586796T1 (sl) 2017-04-26
DK2203478T3 (da) 2014-02-10
JP2011502470A (ja) 2011-01-27
AU2008309514B2 (en) 2011-06-23
EP2203478B1 (en) 2013-11-20
EA018756B1 (ru) 2013-10-30
GT201000085A (es) 2014-03-14
KR20100074271A (ko) 2010-07-01
TN2010000140A1 (en) 2011-09-26
CL2008003004A1 (es) 2009-06-26
PT2203478E (pt) 2014-02-25
PT2586796T (pt) 2017-03-15
CN101821291B (zh) 2013-04-10
US8246953B2 (en) 2012-08-21
WO2009047356A1 (en) 2009-04-16
MX2010003915A (es) 2010-04-30
EP2586796A1 (en) 2013-05-01
ES2448542T3 (es) 2014-03-14
US7879322B2 (en) 2011-02-01
JP2016121170A (ja) 2016-07-07
CR11313A (es) 2010-05-06
ES2614328T3 (es) 2017-05-30
KR20130029452A (ko) 2013-03-22
CU20100059A7 (es) 2012-06-29
CY1114872T1 (el) 2016-12-14
AR068767A1 (es) 2009-12-02
EP2586796B1 (en) 2016-12-07
US8486661B2 (en) 2013-07-16
US20090130113A1 (en) 2009-05-21
CU23869B1 (es) 2013-03-27

Similar Documents

Publication Publication Date Title
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
CU23871B1 (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1
BRPI1012676A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1012560A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
PT2424372T (pt) Composições antimicrobianas e métodos de uso relacionados
BRPI0813514A2 (pt) anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
PT2474557E (pt) Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
PT2247620T (pt) Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI1005670A2 (pt) composições adjuvantes e métodos de uso
BRPI0820407A2 (pt) Uso de anticorpos anti-cd40
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BRPI1014544A8 (pt) anticorpos anti-il-17f e metodos de uso dos mesmos
BRPI0906980A2 (pt) Composição de derivados e maleatados
DOP2011000059A (es) Composiciones de antagonistas de pd-1 y metodos de uso
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0915717A2 (pt) ferramenta de avaliação de cascalho e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/10/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.